Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Use These ETFs as Health Stocks LLY, UNH, MRK Thrive
08:46am, Friday, 17'th Jul 2026
Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company.
Eli Lilly's $3.8bn psychedelics bet is built on British science
05:09am, Friday, 17'th Jul 2026
Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 billion, is above all a vindication of two decades of British research once dismissed as fringe science.
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
04:59pm, Thursday, 16'th Jul 2026
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
01:58pm, Thursday, 16'th Jul 2026
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
01:53pm, Thursday, 16'th Jul 2026
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.
Why Is GH Research Stock Trading Higher on Thursday?
12:36pm, Thursday, 16'th Jul 2026
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal
12:35pm, Thursday, 16'th Jul 2026
Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal that values the clinical-stage mental health biotechnology company at up to approximately $3.8 billio
Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027
09:16am, Thursday, 16'th Jul 2026
A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000
Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC's ‘Final Trades'
08:53am, Thursday, 16'th Jul 2026
On CNBC's “Halftime Report Final Trades,” Bill Baruch, founder and CIO of both Blue Line Capital, an investment advisor, and Blue Creek Capital Management, named Eli Lilly and Company (NYSE:LLY) a
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
08:52am, Thursday, 16'th Jul 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
07:23am, Thursday, 16'th Jul 2026
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
06:45am, Thursday, 16'th Jul 2026
Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing several psychedelics for mental health conditions.
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
06:45am, Thursday, 16'th Jul 2026
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging
AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion
06:15am, Thursday, 16'th Jul 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...
This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
05:36am, Thursday, 16'th Jul 2026
Eli Lilly is in talks to buy a psychedelic drugmaker at a premium, according to a report.
